Matthias Theobald

Prof. Dr. Matthias Theobald

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2008 in Cancer Research
Verified
Journal Article
Open access
PDF file
PHPatricia S. Hähnel
Patricia S. Hähnel
STSonja Thaler
Sonja Thaler
EAEdite Antunes
Edite Antunes
CHChristoph Huber
Christoph Huber
MTMatthias Theobald
Matthias Theobald
MSMartin Schuler
Martin Schuler
The promise of cancer immunotherapy is long-term disease control with high specificity and low toxicity. However, many cancers fail immune interventions, and secretion of immunosuppressive factors, defective antigen presentation, and expression of death ligands or serpins are regarded as main escape mechanisms. Here, we study whether deregulation of growth and survival factor signaling, which is encountered in most human cancers, provides another level of protection against immunologic tumor eradication. We show in two models that activated cell autonomous protein kinase B (PKB)/AKT signaling mediates resistance against tumor suppression by antigen-specific CTLs in vitro and adoptively transferred cellular immune effectors in vivo. PKB/AKT-dependent immunoresistance of established tumors is reversed by genetic suppression of endogenous Mcl-1, an antiapoptotic member of the Bcl-2 family. Mechanistically, deregulated PKB/AKT stabilizes Mcl-1 expression in a mammalian target of rapamycin (mTOR)–dependent pathway. Treatment with the mTOR inhibitor rapamycin effectively sensitizes established cancers to adoptive immunotherapy in vivo. In conclusion, cancer cell–intrinsic PKB/AKT signaling regulates the susceptibility to immune-mediated cytotoxicity. Combined targeting of signal transduction pathways may be critical for improvement of cancer immunotherapies. [Cancer Res 2008;68(10):3899–906]

26 March 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
DKDiana Knies
Diana Knies
SKSebastian Klobuch
Sebastian Klobuch
SXShao-An Xue
Shao-An Xue
MBMatthias Birtel
Matthias Birtel
HEHakim Echchannaoui
Hakim Echchannaoui
RVRalf-Holger Voss
Ralf-Holger Voss
An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells

3 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AAAstrid Alflen
Astrid Alflen
NSNicole Stadler
Nicole Stadler
PLPamela Aranda Lopez
Pamela Aranda Lopez
DTDaniel Teschner
Daniel Teschner
MTMatthias Theobald
Matthias Theobald
Markus RadsakMarkus Radsak
Markus Radsak
Triggering receptor expressed on myeloid cells (TREM)-1 on polymorphonuclear neutrophils (PMN) regulates innate immune activation in infectious and non-infectious conditions. TREM-1 ligation activates phosphatidyl-inositol 3 kinase (PI3K) triggering all neutrophil effector functions. As idelalisib is a PI3K inhibitor in clinical use for the treatment of non-Hodgkin lymphomas, we asked whether this inhibitor affects PMN functionalities. We analyzed PMNs from healthy donors or lymphoma patients for oxidative burst, phagocytosis, activation markers and IL-8 release upon TREM-1 or TLR ligation ex vivo. In addition, we performed western blot analyses to characterize the signaling events inhibited by idelalisib and other PI3K inhibitors. Upon TREM-1 ligation, the oxidative burst, degranulation, L-selectin shedding and cytokine release were all strongly reduced in the presence of idelalisib along impaired phosphorylation of P38, AKT and ERK by western blot analyses. In line with this, PMNs from patients receiving idelalisib also displayed an impaired TREM-1 mediated PMN activation ex vivo. In conclusion, PI3K inhibitors might cause a neutropenia-like susceptibility to infections in patients by leading to impaired PMN functionality. This should be considered when evaluating patients for infections treated with such inhibitors in daily clinical routine.

18 August 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
MBMatthias Birtel
Matthias Birtel
RVRalf-Holger Voss
Ralf-Holger Voss
KRKatharina Reinhard
Katharina Reinhard
BRBenjamin Rengstl
Benjamin Rengstl
YOYasmina Ouchan
Yasmina Ouchan
USUgur Sahin
Ugur Sahin
Chimeric antigen receptor (CAR) T cells are efficacious in patients with B-cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pairing and integration into the T-cell CD3 signaling complex. The TCAR mediated high antigen sensitivity and potent antigen-specific T-cell effector functions in short-term in vitro assays. Both persistence and functionality of TCAR T cells were augmented by provision of costimulatory signals, which improved proliferation in vitro and in vivo. Combination with a nanoparticulate RNA vaccine, developed for in vivo expansion of CAR T cells, promoted tightly controlled expansion, survival, and antitumor efficacy of TCAR T cells in vivo.Significance: A novel TCAR is tightly controlled by RNA vaccine–mediated costimulation and may provide an alternative to second-generation CARs for the treatment of solid tumors.

1 June 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
FRFrederic Ries
Frederic Ries
AAAstrid Alflen
Astrid Alflen
PLPamela Aranda Lopez
Pamela Aranda Lopez
HBHendrik Beckert
Hendrik Beckert
MTMatthias Theobald
Matthias Theobald
Markus RadsakMarkus Radsak
Markus Radsak
There is a growing body of evidence for immunomodulatory side effects of antifungal agents on different immune cells, e.g., T cells. Therefore, the aim of our study was to clarify these interactions with regard to the effector functions of polymorphonuclear neutrophils (PMN). Human PMN were preincubated with fluconazole (FLC), voriconazole (VRC), posaconazole (POS), isavuconazole (ISA), caspofungin (CAS), micafungin (MFG), conventional amphotericin B (AMB), and liposomal amphotericin B (LAMB). PMN then were analyzed by flow cytometry for activation, degranulation, and phagocytosis and by dichlorofluorescein assay to detect reactive oxygen species (ROS). Additionally, interleukin-8 (IL-8) release was measured by enzyme-linked immunosorbent assay. POS led to enhanced activation, degranulation, and generation of ROS, whereas IL-8 release was reduced. In contrast, ISA-pretreated PMN showed decreased activation signaling, impaired degranulation, and lower generation of ROS. MFG caused enhanced expression of activation markers but impaired degranulation, phagocytosis, generation of ROS, and IL-8 release. CAS showed increased phagocytosis, whereas degranulation and generation of ROS were reduced. AMB led to activation of almost all effector functions besides impaired phagocytosis, whereas LAMB did not alter any effector functions. Independent from class, antifungal agents show variable influence on neutrophil effector functions in vitro. Whether this is clinically relevant needs to be clarified.

16 May 2008 in Cancer Letters
Verified
Journal Article
Closed access
VAVijay Alla
Vijay Alla
AKAnubha Kashyap
Anubha Kashyap
SGSebastian Gregor
Sebastian Gregor
MTMatthias Theobald
Matthias Theobald
HHHans Heid
Hans Heid
Susanne StrandSusanne Strand
Susanne Strand